Capricor Therapeutics (CAPR) names CCO Michael Maurer as SEC reporting insider

Rhea-AI Filing Summary

CAPRICOR THERAPEUTICS, INC. filed an initial insider ownership report on Form 3 for Michael T. Maurer, who serves as Chief Commercial Officer. The filing identifies him as a reporting person under SEC rules, and the provided summary shows no insider transactions or derivative holdings.

Key Terms

Form 3, CHIEF COMMERCIAL OFFICER, reportingPersons

3 terms

Form 3 regulatory

"INSIDER FILING DATA (Form 3):"

Form 3 is the initial public filing that officers, directors and large shareholders must submit to report their ownership of a company’s securities when they become insiders. It acts like an opening inventory sheet that gives investors a starting point to see who holds significant stakes and to spot later trades or potential conflicts of interest, helping assess insider confidence and transparency.

CHIEF COMMERCIAL OFFICER financial

""officer_title": "CHIEF COMMERCIAL OFFICER""

A chief commercial officer (CCO) is the senior executive responsible for a company’s revenue-generating activities, including sales, marketing, pricing, customer relationships and business development. Think of the CCO as the head coach who builds the game plan to win customers and grow sales; their effectiveness affects how fast a company earns money, enters new markets and sustains profits, making the role a key signal for investors about future revenue and competitive strength.

reportingPersons regulatory

""reportingPersons": ["

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Understanding Insider Trading Forms →

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Maurer Michael T

(Last) (First) (Middle)

C/O CAPRICOR THERAPEUTICS, INC.

10865 ROAD TO THE CURE, SUITE 150

(Street)

SAN DIEGO CALIFORNIA 92121

(City) (State) (Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
05/25/2026

3. Issuer Name and Ticker or Trading Symbol
CAPRICOR THERAPEUTICS, INC. [ CAPR ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CHIEF COMMERCIAL OFFICER

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

Remarks:

Exhibit 24 - Power of Attorney

No securities are beneficially owned.

	/s/ Linda Marban, Attorney-in-Fact	05/28/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)

FAQ

What does the CAPR Form 3 filing for Michael T. Maurer show?

The Form 3 identifies Michael T. Maurer as a reporting person and Chief Commercial Officer of Capricor Therapeutics. The summarized data shows no reported purchases, sales, or derivative transactions in this initial ownership statement.

Who is the insider named in Capricor Therapeutics (CAPR) Form 3?

The insider is Michael T. Maurer, listed as the Chief Commercial Officer of Capricor Therapeutics. He is designated as a reporting person subject to SEC insider reporting requirements under Section 16 of the Securities Exchange Act.

Does the CAPR Form 3 for Michael T. Maurer report any stock transactions?

The summarized Form 3 data shows no reported buy, sell, gift, or exercise transactions. All transaction counters, including buys, sells, and derivative exercises, are reported as zero in the transaction summary for this filing.

Are any derivative securities reported in the Capricor (CAPR) Form 3 for Maurer?

The filing summary lists an empty derivativeSummary, indicating no derivative securities such as options or warrants are disclosed in this Form 3 excerpt for Michael T. Maurer as Chief Commercial Officer.

What is the role of Michael T. Maurer at Capricor Therapeutics (CAPR)?

Michael T. Maurer is reported as the Chief Commercial Officer of Capricor Therapeutics. In this capacity, he is treated as an officer and a reporting person for SEC insider disclosure purposes on Form 3.